OTCMKTS:GBLX

GB Sciences - GBLX Stock Forecast, Price & News

$0.03

0.00 (0.00%)

(As of 10/3/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.03
▼
$0.03
52-Week Range: $0.02
▼
$0.04

Volume: 97,702 shs
Average Volume: 185,826 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About GB Sciences (OTCMKTS:GBLX) Stock

GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Receive GBLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GB Sciences and its competitors with MarketBeat's FREE daily newsletter.

GBLX Stock News Headlines

September 6, 2022 | finance.yahoo.com

TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article

August 9, 2022 | ca.finance.yahoo.com

GB Sciences, Inc. (GBLX)

July 19, 2022 | finance.yahoo.com

Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™

July 18, 2022 | finance.yahoo.com

Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™

May 23, 2022 | finance.yahoo.com

TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit

May 12, 2022 | finance.yahoo.com

TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit

May 5, 2022 | finance.yahoo.com

TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference

May 2, 2022 | finance.yahoo.com

FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies

April 17, 2022 | msn.com

Gb Sciences To Begin Dosage Study For Cannabinoid-Containing Drug For Treatment Of Parkinson's Disease

April 12, 2022 | finance.yahoo.com

Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge

March 29, 2022 | finance.yahoo.com

Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article

March 16, 2022 | finance.yahoo.com

UPDATE: Gb Sciences Issues Shareholder Letter

March 15, 2022 | finance.yahoo.com

Gb Sciences Issues Summary Shareholder Letter

March 1, 2022 | seekingalpha.com

Gb Sciences gets US patent for cannabinoid-containing mixture to treat heart disease

March 1, 2022 | finance.yahoo.com

Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis

February 1, 2022 | msn.com

Not So Fast With The Cannabis-COVID Treatment: Gb Sciences And Michigan State U Researchers Clarify

February 1, 2022 | finance.yahoo.com

Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment

January 11, 2022 | msn.com

Gb Sciences Leaves Cannabis Cultivation With $8M Sale Of Las Vegas Facility, Enters BioPharma Industry

January 11, 2022 | finance.yahoo.com

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

December 6, 2021 | finance.yahoo.com

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

November 1, 2021 | finance.yahoo.com

Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety

September 14, 2021 | finance.yahoo.com

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

September 9, 2021 | finance.yahoo.com

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference

August 10, 2021 | finance.yahoo.com

Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021

July 27, 2021 | finance.yahoo.com

GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GBLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GB Sciences and its competitors with MarketBeat's FREE daily newsletter.

GBLX Company Calendar

Last Earnings: 11/14/2016
Today: 10/04/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: Cannabis
Sector: Medical
Current Symbol: OTCMKTS:GBLX
CUSIP: N/A
CIK: 1165320
Web: gbsciences.com
Phone: (866) 721-0297
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. John Claybron Poss (Age 74)
Chairman & CEO
Comp: $102.82k

Dr. Andrea Small-Howard M.B.A. (Age 53)
MBA, Ph.D., Chairman of Scientific Advisory Board, Chief Science Officer, Pres & Director
Comp: $177.85k

Mr. Zach Swarts (Age 34)
CFO, Chief Accounting Officer & Treasurer
Comp: $128.25k

Mr. Krin Ellery Kuethe (Age 38)
Sr. VP of Cultivation

Mr. Gary R. Henrie Esq.
Securities Counsel & Company Sec.

Key Competitors

View All Competitors

GBLX Stock - Frequently Asked Questions

How have GBLX shares performed in 2022?: GB Sciences' stock was trading at $0.0205 at the start of the year. Since then, GBLX stock has increased by 31.2% and is now trading at $0.0269.
View the best growth stocks for 2022 here.
Are investors shorting GB Sciences?: GB Sciences saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 34,200 shares, an increase of 100.0% from the August 31st total of 17,100 shares. Based on an average daily trading volume, of 155,300 shares, the days-to-cover ratio is currently 0.2 days.
View GB Sciences' Short Interest.
How were GB Sciences' earnings last quarter?: GB Sciences, Inc. (OTCMKTS:GBLX) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter.

What other stocks do shareholders of GB Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GB Sciences investors own include KushCo (KSHB), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MassRoots (MSRT), Surna (SRNA), Gran Tierra Energy (GTE), GreenGro Technologies (GRNH), MariMed (MRMD), Pennsylvania Real Estate Investment Trust (PEI) and PotNetwork (POTN).
What is GB Sciences' stock symbol?: GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."
How do I buy shares of GB Sciences?: Shares of GBLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GB Sciences' stock price today?: One share of GBLX stock can currently be purchased for approximately $0.03.
How can I contact GB Sciences?: GB Sciences' mailing address is 6450 Cameron St Ste 110A, LAS VEGAS, NV 89118-4337, United States. The official website for the company is gbsciences.com. The company can be reached via phone at (866) 721-0297.

This page (OTCMKTS:GBLX) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms